Synbody: Tackling tough targets

Synbody developing peptide-based ligands against undruggable targets

Synbody Biotechnology Inc. is using synthetic peptides to create flexible, modular ligands that have high affinity and specificity for their targets. The biotech says its ligands - dubbed synbodies - are easy to manufacture and will be useful for hitting targets that would otherwise be difficult to drug with small molecules and antibodies.

Synbody was founded to commercialize a technology invented by Arizona State University researchers for discovering and engineering peptide-based ligands. The company has exclusively licensed five patent families

Read the full 798 word article

How to gain access

Continue reading with a
two-week free trial.